Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Complex medical history of a patient with a compound heterozygous mutation in C1QC.

Lubbers R, Beaart-van de Voorde LJJ, van Leeuwen K, de Boer M, Gelderman KA, van den Berg MJ, Ketel AG, Simon A, de Ree J, Huizinga TWJ, Steup-Beekman GM, Trouw LA.

Lupus. 2019 Sep;28(10):1255-1260. doi: 10.1177/0961203319865029. Epub 2019 Jul 29.

2.

Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis.

van de Lest NA, Zandbergen M, Wolterbeek R, Kreutz R, Trouw LA, Dorresteijn EM, Bruijn JA, Bajema IM, Scharpfenecker M, Chua JS.

Kidney Int. 2019 Sep;96(3):738-749. doi: 10.1016/j.kint.2019.04.028. Epub 2019 May 16.

PMID:
31327475
3.

Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification.

Kampstra ASB, Dekkers JS, Volkov M, Dorjée AL, Hafkenscheid L, Kempers AC, van Delft M, Kissel T, Reijm S, Janssen GMC, van Veelen PA, Bang H, Huizinga TWJ, Trouw LA, van der Woude D, Toes REM.

Ann Rheum Dis. 2019 Jul;78(7):908-916. doi: 10.1136/annrheumdis-2018-214950. Epub 2019 May 31.

PMID:
31151934
4.

Screening for two or three autoantibodies in persons at risk for RA: implications of current data for clinical practice.

Ten Brinck RM, Trouw LA, van der Helm-van Mil AHM.

Rheumatology (Oxford). 2019 May 1;58(5):914-915. doi: 10.1093/rheumatology/key441. No abstract available.

PMID:
30753673
5.

In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Collée G, Lard LR, Ramiro S, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Arthritis Res Ther. 2019 Jan 18;21(1):28. doi: 10.1186/s13075-019-1815-0.

6.

Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population.

Gaya da Costa M, Poppelaars F, van Kooten C, Mollnes TE, Tedesco F, Würzner R, Trouw LA, Truedsson L, Daha MR, Roos A, Seelen MA.

Front Immunol. 2018 Nov 20;9:2664. doi: 10.3389/fimmu.2018.02664. eCollection 2018.

7.

The role of complement in antineutrophil cytoplasmic antibody-associated vasculitis.

Wester Trejo MAC, Trouw LA, Bajema IM.

Curr Opin Rheumatol. 2019 Jan;31(1):3-8. doi: 10.1097/BOR.0000000000000557.

PMID:
30461541
8.

Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis.

Lubbers R, Sutherland JS, Goletti D, de Paus RA, van Moorsel CHM, Veltkamp M, Vestjens SMT, Bos WJW, Petrone L, Del Nonno F, Bajema IM, Dijkman K, Verreck FAW, Walzl G, Gelderman KA, Groeneveld GH, Geluk A, Ottenhoff THM, Joosten SA, Trouw LA.

Front Immunol. 2018 Oct 23;9:2427. doi: 10.3389/fimmu.2018.02427. eCollection 2018.

9.

Presence of Autoantibodies in Erosive Hand Osteoarthritis and Association with Clinical Presentation.

van Delft MAM, van Beest S, Kloppenburg M, Trouw LA, Ioan-Facsinay A.

J Rheumatol. 2019 Jan;46(1):101-105. doi: 10.3899/jrheum.180256. Epub 2018 Sep 15.

PMID:
30219766
10.

Secretory form of rheumatoid arthritis-associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces.

van Delft MAM, van der Woude D, Toes REM, Trouw LA.

Ann Rheum Dis. 2019 Jan;78(1):146-148. doi: 10.1136/annrheumdis-2018-213724. Epub 2018 Aug 14. No abstract available.

PMID:
30108046
11.

Anti-Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis-A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al.

Derksen VFAM, Trouw LA, Huizinga TWJ, van der Helm-van Mil AHM, Knevel R, Westerlind H, Saevarsdottir S, Ajeganova S, van der Woude D.

Arthritis Rheumatol. 2018 Dec;70(12):2096-2097. doi: 10.1002/art.40678. Epub 2018 Oct 27. No abstract available.

PMID:
30058116
12.

In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission.

de Moel EC, Derksen VFAM, Trouw LA, Bang H, Goekoop-Ruiterman YPM, Steup-Beekman GM, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Ann Rheum Dis. 2018 Dec;77(12):1836-1838. doi: 10.1136/annrheumdis-2018-213823. Epub 2018 Jul 25. No abstract available.

PMID:
30045852
13.

The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching.

van Delft MAM, Verheul MK, Burgers LE, Rantapää-Dahlqvist S, van der Helm-van Mil AHM, Huizinga TWJ, Toes REM, Trouw LA.

Rheumatology (Oxford). 2018 Sep 1;57(9):1583-1591. doi: 10.1093/rheumatology/key135.

PMID:
29846726
14.

Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals.

Verheul MK, Böhringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, Holers VM, Edison JD, Deane KD, Janssen KMJ, Westra J, Brink M, Rantapää-Dahlqvist S, Huizinga TWJ, van der Helm-van Mil AHM, van der Woude D, Toes REM, Trouw LA.

Arthritis Rheumatol. 2018 Nov;70(11):1721-1731. doi: 10.1002/art.40562. Epub 2018 Sep 16. Review.

PMID:
29781231
15.

Complement Activation in Patients With Diabetic Nephropathy.

Bus P, Chua JS, Klessens CQF, Zandbergen M, Wolterbeek R, van Kooten C, Trouw LA, Bruijn JA, Baelde HJ.

Kidney Int Rep. 2017 Oct 16;3(2):302-313. doi: 10.1016/j.ekir.2017.10.005. eCollection 2018 Mar.

16.

Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example.

Boeters DM, Trouw LA, van der Helm-van Mil AHM, van Steenbergen HW.

Arthritis Res Ther. 2018 May 3;20(1):94. doi: 10.1186/s13075-018-1591-2.

17.

Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes.

de Moel EC, Derksen VFAM, Stoeken G, Trouw LA, Bang H, Goekoop RJ, Speyer I, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D.

Arthritis Res Ther. 2018 Feb 26;20(1):33. doi: 10.1186/s13075-018-1520-4.

18.

Pitfalls in the detection of citrullination and carbamylation.

Verheul MK, van Veelen PA, van Delft MAM, de Ru A, Janssen GMC, Rispens T, Toes REM, Trouw LA.

Autoimmun Rev. 2018 Feb;17(2):136-141. doi: 10.1016/j.autrev.2017.11.017. Epub 2017 Dec 2. Review.

19.

Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis.

Verheul MK, Vierboom MPM, 't Hart BA, Toes REM, Trouw LA.

Arthritis Res Ther. 2017 Nov 2;19(1):246. doi: 10.1186/s13075-017-1455-1.

20.

The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia.

Ten Brinck RM, van Steenbergen HW, van Delft MAM, Verheul MK, Toes REM, Trouw LA, van der Helm-van Mil AHM.

Rheumatology (Oxford). 2017 Dec 1;56(12):2145-2153. doi: 10.1093/rheumatology/kex340.

21.

The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients.

van Delft MAM, Verheul MK, Burgers LE, Derksen VFAM, van der Helm-van Mil AHM, van der Woude D, Huizinga TWJ, Toes REM, Trouw LA.

Arthritis Res Ther. 2017 Aug 15;19(1):190. doi: 10.1186/s13075-017-1392-z.

22.

The complement system as a potential therapeutic target in rheumatic disease.

Trouw LA, Pickering MC, Blom AM.

Nat Rev Rheumatol. 2017 Sep;13(9):538-547. doi: 10.1038/nrrheum.2017.125. Epub 2017 Aug 10. Review.

PMID:
28794515
23.

The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM.

Kempers AC, Hafkenscheid L, Dorjée AL, Moutousidou E, van de Bovenkamp FS, Rispens T, Trouw LA, van Oosterhout M, Huizinga TW, Toes R, Scherer HU.

Ann Rheum Dis. 2018 Jul;77(7):1087-1088. doi: 10.1136/annrheumdis-2017-211533. Epub 2017 Jul 26. No abstract available.

PMID:
28747327
24.

Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays.

Vos I, Van Mol C, Trouw LA, Mahler M, Bakker JA, Van Offel J, De Clerck L, Huizinga TW.

Clin Rheumatol. 2017 Jul;36(7):1487-1492. doi: 10.1007/s10067-017-3684-8. Epub 2017 Jun 3.

25.

The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical.

Boeters DM, Mangnus L, Ajeganova S, Lindqvist E, Svensson B, Toes REM, Trouw LA, Huizinga TWJ, Berenbaum F, Morel J, Rantapää-Dahlqvist S, van der Helm-van Mil AHM.

Arthritis Res Ther. 2017 May 31;19(1):115. doi: 10.1186/s13075-017-1324-y.

26.

Breach of autoreactive B cell tolerance by post-translationally modified proteins.

Dekkers JS, Verheul MK, Stoop JN, Liu B, Ioan-Facsinay A, van Veelen PA, de Ru AH, Janssen GMC, Hegen M, Rapecki S, Huizinga TWJ, Trouw LA, Toes REM.

Ann Rheum Dis. 2017 Aug;76(8):1449-1457. doi: 10.1136/annrheumdis-2016-210772. Epub 2017 Apr 25.

PMID:
28442530
27.

C1q-Dependent Dendritic Cell Cross-Presentation of In Vivo-Formed Antigen-Antibody Complexes.

Ho NI, Camps MGM, de Haas EFE, Trouw LA, Verbeek JS, Ossendorp F.

J Immunol. 2017 Jun 1;198(11):4235-4243. doi: 10.4049/jimmunol.1602169. Epub 2017 Apr 21.

28.

Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production.

Castañeda-Delgado JE, Bastián-Hernandez Y, Macias-Segura N, Santiago-Algarra D, Castillo-Ortiz JD, Alemán-Navarro AL, Martínez-Tejada P, Enciso-Moreno L, Garcia-De Lira Y, Olguín-Calderón D, Trouw LA, Ramos-Remus C, Enciso-Moreno JA.

Front Immunol. 2017 Mar 20;8:285. doi: 10.3389/fimmu.2017.00285. eCollection 2017.

29.

Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis.

Verheul MK, Yee A, Seaman A, Janssen GM, van Veelen PA, Drijfhout JW, Toes REM, Mahler M, Trouw LA.

J Autoimmun. 2017 Jun;80:77-84. doi: 10.1016/j.jaut.2017.02.008. Epub 2017 Mar 11.

PMID:
28291659
30.

Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present.

Derksen VF, Ajeganova S, Trouw LA, van der Helm-van Mil AH, Hafström I, Huizinga TW, Toes RE, Svensson B, van der Woude D.

Ann Rheum Dis. 2017 Apr;76(4):716-720. doi: 10.1136/annrheumdis-2016-209794. Epub 2016 Nov 9.

PMID:
28283528
31.

Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.

Trouw LA, Rispens T, Toes REM.

Nat Rev Rheumatol. 2017 Jun;13(6):331-339. doi: 10.1038/nrrheum.2017.15. Epub 2017 Mar 9. Review.

PMID:
28275265
32.

Identification of Lifelines participants at high risk for development of rheumatoid arthritis.

Arends S, Trouw LA, Toes REM, van Zanten A, Roozendaal C, Limburg PC, Bootsma H, Brouwer E.

Ann Rheum Dis. 2017 Nov;76(11):e43. doi: 10.1136/annrheumdis-2017-211256. Epub 2017 Mar 8. No abstract available.

PMID:
28274913
33.

Production of complement components by cells of the immune system.

Lubbers R, van Essen MF, van Kooten C, Trouw LA.

Clin Exp Immunol. 2017 May;188(2):183-194. doi: 10.1111/cei.12952. Epub 2017 Mar 24. Review.

34.

C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus.

van Schaarenburg RA, Magro-Checa C, Bakker JA, Teng YK, Bajema IM, Huizinga TW, Steup-Beekman GM, Trouw LA.

Front Immunol. 2016 Dec 27;7:647. doi: 10.3389/fimmu.2016.00647. eCollection 2016.

35.

Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands.

van Zanten A, Arends S, Roozendaal C, Limburg PC, Maas F, Trouw LA, Toes REM, Huizinga TWJ, Bootsma H, Brouwer E.

Ann Rheum Dis. 2017 Jul;76(7):1184-1190. doi: 10.1136/annrheumdis-2016-209991. Epub 2017 Jan 2.

36.

Excretions/secretions from medicinal larvae (Lucilia sericata) inhibit complement activation by two mechanisms.

Tamura T, Cazander G, Rooijakkers SH, Trouw LA, Nibbering PH.

Wound Repair Regen. 2017 Jan;25(1):41-50. doi: 10.1111/wrr.12504. Epub 2017 Mar 6.

PMID:
28019718
37.

Short article: Absence of serological rheumatoid arthritis biomarkers in inflammatory bowel disease patients with arthropathies.

Van Erp SJ, Verheul MK, Levarht EW, van der Reijden JJ, van der Heijde D, van Gaalen FA, Hommes DW, Norman GL, Shums Z, Mahler M, Verspaget HW, Trouw LA, van der Meulen-de Jong AE.

Eur J Gastroenterol Hepatol. 2017 Mar;29(3):345-348. doi: 10.1097/MEG.0000000000000805.

PMID:
27926664
38.

Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts.

Ziegelasch M, van Delft MA, Wallin P, Skogh T, Magro-Checa C, Steup-Beekman GM, Trouw LA, Kastbom A, Sjöwall C.

Arthritis Res Ther. 2016 Dec 3;18(1):289.

39.

Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study.

van Wesemael TJ, Ajeganova S, Humphreys J, Terao C, Muhammad A, Symmons DP, MacGregor AJ, Hafström I, Trouw LA, van der Helm-van Mil AH, Huizinga TW, Mimori T, Toes RE, Matsuda F, Svensson B, Verstappen SM, van der Woude D.

Arthritis Res Ther. 2016 Dec 1;18(1):285.

40.

Reply.

Hitchon CA, Koppejan H, Trouw LA, Huizinga TJ, Toes RE, El-Gabalawy HS.

Arthritis Rheumatol. 2016 Nov;68(11):2826-2827. doi: 10.1002/art.39831. Epub 2016 Oct 9. No abstract available.

41.

The production and secretion of complement component C1q by human mast cells.

van Schaarenburg RA, Suurmond J, Habets KL, Brouwer MC, Wouters D, Kurreeman FA, Huizinga TW, Toes RE, Trouw LA.

Mol Immunol. 2016 Oct;78:164-170. doi: 10.1016/j.molimm.2016.09.001. Epub 2016 Sep 17.

42.

Rheumatoid arthritis: Autoantibody testing to predict response to therapy in RA.

Trouw LA, Toes RE.

Nat Rev Rheumatol. 2016 Oct;12(10):566-8. doi: 10.1038/nrrheum.2016.151. Epub 2016 Sep 15. No abstract available.

PMID:
27627867
43.

MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF.

Boeters DM, Nieuwenhuis WP, Verheul MK, Newsum EC, Reijnierse M, Toes RE, Trouw LA, van der Helm-van Mil AH.

Arthritis Res Ther. 2016 Aug 2;18:179. doi: 10.1186/s13075-016-1076-0.

44.

Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus.

Magro-Checa C, Schaarenburg RA, Beaart HJ, Huizinga TW, Steup-Beekman GM, Trouw LA.

Lupus. 2016 Jul;25(8):878-88. doi: 10.1177/0961203316643170.

PMID:
27252265
45.

Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation.

Verheul MK, van Erp SJ, van der Woude D, Levarht EW, Mallat MJ, Verspaget HW, Stolk J, Toes RE, van der Meulen-de Jong AE, Hiemstra PS, van Kooten C, Trouw LA.

Ann Rheum Dis. 2016 Aug;75(8):1575-6. doi: 10.1136/annrheumdis-2016-209248. Epub 2016 Apr 29. No abstract available.

PMID:
27130909
46.

The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor.

Ajeganova S, van Steenbergen HW, Verheul MK, Forslind K, Hafström I, Toes RE, Huizinga TW, Svensson B, Trouw LA, van der Helm-van Mil AH.

Ann Rheum Dis. 2017 Jan;76(1):112-118. doi: 10.1136/annrheumdis-2015-208870. Epub 2016 Apr 26.

PMID:
27117699
47.

Role of Anti-Carbamylated Protein Antibodies Compared to Anti-Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their First-Degree Relatives, and Healthy Controls.

Koppejan H, Trouw LA, Sokolove J, Lahey LJ, Huizinga TJ, Smolik IA, Robinson DB, El-Gabalawy HS, Toes RE, Hitchon CA.

Arthritis Rheumatol. 2016 Sep;68(9):2090-8. doi: 10.1002/art.39664.

48.

Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study.

Akdemir G, Verheul MK, Heimans L, Wevers-de Boer KV, Goekoop-Ruiterman YP, van Oosterhout M, Harbers JB, Bijkerk C, Steup-Beekman GM, Lard LR, Huizinga TW, Trouw LA, Allaart CF.

RMD Open. 2016 Feb 15;2(1):e000172. doi: 10.1136/rmdopen-2015-000172. eCollection 2016.

49.

Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis.

Brink M, Hansson M, Mathsson-Alm L, Wijayatunga P, Verheul MK, Trouw LA, Holmdahl R, Rönnelid J, Klareskog L, Rantapää-Dahlqvist S.

Arthritis Res Ther. 2016 Feb 9;18:43. doi: 10.1186/s13075-016-0940-2.

50.

Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts.

Ajeganova S, Humphreys JH, Verheul MK, van Steenbergen HW, van Nies JA, Hafström I, Svensson B, Huizinga TW, Trouw LA, Verstappen SM, van der Helm-van Mil AH.

Ann Rheum Dis. 2016 Nov;75(11):1924-1932. doi: 10.1136/annrheumdis-2015-208579. Epub 2016 Jan 12.

PMID:
26757747

Supplemental Content

Loading ...
Support Center